Sales figures reach the next stage

As announced by Bandai Namco Entertainment, the Japanese role-playing game “Tales of Arise” continues to develop into a commercial success. Sales figures have recently reached the next stage.

With “Tales of Arise” Bandai Namco Entertainment released the latest long-running RPG series for consoles and PC in September of last year.

With an expanded team and a new engine, the developers wanted to redesign the Tales series for the future. Successfully, as the sales figures show. After 1.5 million units were delivered and sold digitally in October 2021, “Tales of Arise” has now reached its next commercial stage with 2 million copies sold.

“Today we celebrate a new major milestone with two million copies of Tales of Arise sold! We are very grateful for your valuable support,” said Bandai Namco Entertainment. Thank you.

No direct heir planned

Even if direct successors like “Tales of Xillia 2” or “Tales of Symphonia: Dawn of the New World” have been released in the past, the commercial success of “Tales of Arise” won’t mean that a similar sequel is made on will. Producer Yusuke Tomioza explained this recently and justified the focus on an entirely new branch with the challenge of opening new target groups for the Tales series.

“We want to continue to take on the challenge of attracting new fans for the ever expanding RPG. To do that, we need to create a cutting-edge flagship title that builds on the success of Arise while providing an opportunity to rediscover the history of the series.” so product.

See also  Watch Dogs Legion: Crossover Begins With 'Money Heist'

Tales of Arise is available for PC, PlayStation 4, PlayStation 5, Xbox One, and Xbox Series X/S.

More stories about the stories of the rise.

Discuss this news on PlayStation Forum

Usually the links to Amazon, Media Markt, Saturn, and some other retailers are affiliate links. If you make a purchase, we receive a small commission that we can use to fund the free to use site. You have no flaws.


Please enter your comment!
Please enter your name here